Impacts of 12-dose regimen for latent tuberculosis infection Treatment completion rate and cost-effectiveness in Taiwan

doi:10.1097/MD.0000000000004126

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/18202

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/18202

Title:	Impacts of 12-dose regimen for latent tuberculosis infection Treatment completion rate and cost-effectiveness in Taiwan
Authors:	Huang, Y.-W.;Yang, S.-F.;Yeh, Yeh Y.-P.;Tsao, Tsao T.C.-Y.;Tsao, S.-M.
Keywords:	Cost-effectiveness;Isoniazid;Latent tuberculosis infection treatment;Rifapentine
Date:	2016
Issue Date:	2017-08-09T03:25:41Z (UTC)
Publisher:	Lippincott Williams and Wilkins
ISSN:	257974
Abstract:	Treatment of latent tuberculosis infection (LTBI) is essential for eradicating tuberculosis (TB).Moreover, the patient adherence is crucial in determining the effectiveness of TB control. Isoniazid given byDOTS daily for 9months (9H) is the standard treatment for LTBI in Taiwan. However, the completion rate is low due to the long treatment period and its side effects. The combined regimen using a high dose of rifapentine/isoniazid once weekly for 12 weeks (3HP) has been used as an alternative treatment option for LTBI in the United States. This may result in a higher completion rate. In this pilot study, patient adherence and cost of these 2 treatment regimens were investigated. Thus, we aimed to assess the treatment completion rate and costs of 3HP and compare to those with 9H. Data from 691 cases of LTBI treatments including 590 cases using the conventional regimen and 101 cases with rifapentine/ Isoniazid were collected. The cost was the sum of the cost of treatment with Isoniazid for 9 months or with rifapentin/Isoniazid for 3 months of all contacts. The effectiveness was the cost of cases of tuberculosis avoided. In this study, the treatment completion rate for patients prescribed with the 3 months rifapentine/isoniazid regimen (97.03%) was higher than those given the conventional 9-month isoniazid regimen (87.29%) (P<0.001). The cost of 3HP and 9H was US$261.24 and US$717.3, respectively. The cost-effectiveness ratio with isoniazid for 9 months was US$ 15392/avoided 1 case of tuberculosis and US$ 5225/avoided 1 case of tuberculosis with 3HP. In addition, when compared with the conventional regimen, there were fewer patients discontinued with rifapentine/isoniazid regimen due to undesirable side effects. This was the first study to compare the 2 treatment regimens in Taiwan, and it showed that a short-Term high-dosage rifapentine/ isoniazid treatment regimen reduced costs and resulted in higher treatment completion than the standard LTBI isoniazid treatment. Abbreviations: 3HP = 3-month rifapentine/isoniazid regimen, 9H = 9-month isoniazid regimen, DOTS = direct observation of treatment, FDA = Food and Drug Administration, LTBI = latent tuberculosis infection, TB = tuberculosis. © Copyright 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.
URI:	http://dx.doi.org/10.1097/MD.0000000000004126 https://www.scopus.com/inward/record.uri?eid=2-s2.0-84987761874&doi=10.1097%2fMD.0000000000004126&partnerID=40&md5=11390cdc64c0c626456fa66b9f7c5ab8 https://ir.csmu.edu.tw:8080/ir/handle/310902500/18202
Relation:	Medicine (United States) 95(34) ,-
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

There are no files associated with this item.

Loading...